Bizarre Patents
Method and apparatus for making a drink hop along a bar or counter
A method for generating a drink which appears to hop from a remote spot on the bar or counter and take one or more leaps, before landing in a patron's glass.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Application No. | Application Title | Issue Date |
| 20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions.... | 05/24/2012 |
| 20120070434 | ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are us... | 03/22/2012 |
| 20120052042 | AMPHIPHILIC COMPOUNDS AND SELF-ASSEMBLING COMPOSITIONS MADE THEREFROM The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.... | 03/01/2012 |
| 20120045816 | Novel Glycosylated Polypeptides Provided herein are glycosylated polypeptide compositions with substantially reduced Neu5Gc content. The glycosylated polypeptides compositions with substantially reduced Neu5Gc content can be obtained from cell sources cultured with Neu5Gc competitor or from non-human ... | 02/23/2012 |
| 20120039989 | ERYTHROCYTE-BINDING THERAPEUTICS Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fu... | 02/16/2012 |
| 20120035344 | NUCLEOPHILIC CATALYSTS FOR OXIME LINKAGE The invention relates to materials and methods of conjugating a water soluble polymer to an oxidized carbohydrate moiety of a therapeutic protein comprising contacting the oxidized carbohydrate moiety with an activated water soluble polymer under conditions that allow c... | 02/09/2012 |
| 20120010155 | GNTIII EXPRESSION IN PLANTS The invention relates to the field of glycoprotein processing in transgenic plants used as cost efficient and contamination safe factories for the production of recombinant biopharmaceutical proteins or pharmaceutical compositions comprising these glycoproteins. The inv... | 01/12/2012 |
| 20120003712 | METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE The present invention provides a method for preparing a site-specific physiologically active polypeptide conjugate in a high yield by treating a physiologically active polypeptide with a non-peptidyl polymer in the presence of an alcohol at a specific pH, which can be d... | 01/05/2012 |
| 20110318779 | PROCESS FOR PRODUCING RECOMBINANT PROTEIN USING NOVEL FUSION PARTNER The present invention provides a method of producing polypeptide utilizing a fusion protein of A-B type in the following formula (I), by culturing transformed microorganism comprising DNA sequence encoding the desirable polypeptide; A-B (I). In the above formula (I), A ... | 12/29/2011 |
| 20110312027 | Production of Carrier-Peptide Conjugates Using Chemically Reactive Unnatural Amino Acids Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amin... | 12/22/2011 |
| 20110301086 | Complex polymere amphiphile-PDGF Physically and chemically stable, water-soluble, amphiphilic polymer-PDGF complex, characterized in that the amphiphilic polymers include a hydrophilic polymeric backbone functionalized with hydrophobic substituents and hydrophilic groups.... | 12/08/2011 |
| 20110293579 | Bi-specific fusion proteins Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins general... | 12/01/2011 |
| 20110294733 | MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND MANUFACTURING METHOD THEREOF The invention concerns human thrombopoietin and in particular modified forms of thrombopoietin (TPO) with improved properties. The improved proteins contain amino acid substitutions at specific positions within the TPO molecule. The invention provides modified TPO molec... | 12/01/2011 |
| 20110294989 | PROCESSING OF RECOMBINANT HUMAN G-CSF A G-CSF precursor comprising a signal peptide and a G-CSF peptide, wherein the signal peptide has the sequence of the human wild-type signal peptide of the human G-CSF/b molecule with at least one of the following mutations:
| |
| 20110293554 | RECOMBINANT HUMAN G-CSF DIMER AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL DISEASES This invention relates to a recombinant human G-CSF (rhG-CSF) dimer and its use in the treatment of neurological disorder. In particular, upon ischemic neural injury in animal, this invention can be used to protect neurons with the use of rhG-CSF dimer such that functio... | 12/01/2011 |
| 20110280826 | Y-SHAPED POLYETHYLENE GLYCOL MODIFIED G-CSF, THE PREPARATION AND USE THEREOF The present invention relates to granulocyte colony stimulating factor (G-CSF) modified with Y-shaped branched polyethylene glycol (YPEG-G-CSF) at a specific lysine (Lys 17) and the preparation thereof, as well as the pharmaceutical composition comprising YPEG-G-CSF and... | 11/17/2011 |
| 20110275792 | METAL COORDINATED COMPOSITIONS A metal coordination complex of a biologically active moiety and a metal is disclosed. The complex confers to the biologically active moiety an improved performance which can include potency, stability, absorbability, targeted delivery, and combinations thereof.... | 11/10/2011 |
| 20110263500 | Curcumin Conjugates for Treating and Preventing Cancers Conjugating LHRH to curcumin (LHRH-Curcumin) substantially enhances the bioavailability of curcumin, targets it to cells expressing LHRH receptors, facilitates intravenous administration, and increases the anti-cancer efficacy of curcumin. The conjugate may be used agai... | 10/27/2011 |
| 20110262963 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES Disclosed herein is pyrroline-carboxy-lysine (PCL), a pyrrolysine analogue, which is a natural, biosynthetically generated amino acid, and methods for biosynthetically generating PCL. Also disclosed herein are proteins, polypeptides and peptides that have PCL incorporat... | 10/27/2011 |
| 20110263517 | Cytokines and Cytokine Receptors with Reduced Immunogenicity The present invention provides methods for the identification of CD4+ T-cell epitopes in the sequences of various proteins, namely, human cytokines and cytokine receptors, as well as the production of peptides which when incorporated into the protein sequence, are no lo... | 10/27/2011 |
| 20110250169 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to no... | 10/13/2011 |
| 20110236404 | Methods for Protein Expression in Mammalian Cells in Serum-Free Medium Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and va... | 09/29/2011 |
| 20110212518 | EXPRESSION VECTOR AND METHODS OF PRODUCING HIGH LEVELS OF PROTEINS A process for high expression of protein of interest using an expression vector. The process comprises at least the following regulatory elements: a) a CMV promoter, or its functional variants, b) an intron, c) TPL or its functional variants, d) VA genes or functional v... | 09/01/2011 |
| 20110195895 | FGF21 MUTANTS AND USES THEREOF The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmac... | 08/11/2011 |
| 20110189752 | COMPLEX A complex comprising at least one target protein and at least one binding molecule having a binding affinity for said target protein, wherein said molecule having a binding affinity is covalently or non-covalently bound to at least one water-soluble polymer... | 08/04/2011 |
| 20110178011 | Polysaccharide/BMP complexes which are soluble at physiological pH A complex of a polysaccharide and recombinant human BMP-2 and BMP-7, soluble at physiological pH, wherein the polysaccharide/BMP mass ratio is less than 15, the polysaccharide being selected from the group of polysaccharides having carboxyl functional groups, at least o... | 07/21/2011 |
| 20110152506 | Method for Purifying Erythropoietin The present invention relates to a method for preparing erythropoietin, wherein culture supernatant of erythropoietin-producing eukaryotic cells containing erythropoietin are subjected to the following steps: a) Removing the cell components; and b) treating the product ... | 06/23/2011 |
| 20110144281 | AMPHIPHILIC POLYMERS HAVING A CHOLANE CORE The present invention relates to a polymer comprising a cholane core having at least one derivatizable group covalently bonded thereto and a hydrophilic polymer chain covalently bonded to derivatizable group(s) and a process for producing it The present invention also r... | 06/16/2011 |
| 20110135614 | MODIFIED GROWTH HORMONE The invention provides, a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides... | 06/09/2011 |
| 20110129858 | Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof A method for evaluating the cure level of a stroke patient comprises following steps: (1) obtaining isolated blood sample from said stroke patient; (2) determining the concentration of serum granulocyte colony-stimulating factor (G-CSF) of said blood sample; (3) compari... | 06/02/2011 |
| 20110123481 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR THERAPEUTIC AND COSMETIC APPLICATIONS A method of promoting wound healing or connective tissue reconstruction and a method of treating ischemia in a subject in need thereof are disclosed. The methods comprising topically administering to the subject about 10-30 mg per cm2 wound tissue of Erythrop... | 05/26/2011 |
| 20110118448 | Purification of pegylated polypeptides The invention is a method for the purification of mono-PEGylated erythropoietin using two cation exchange chromatography steps wherein the same type of cation exchange material is used in both cation exchange chromatography steps and a method for producing a mono-PEGyla... | 05/19/2011 |
| 20110112018 | Method for the Treatment and/or Prophylaxis of Multiple Sclerosis, and Use of Erythropoietin for the Manufacture of a Medicament for the Intermittent and/or Intermittent Prophylaxis of Multiple Sclerosis The present invention relates to a method for the treatment and/or prophylaxis of multiple sclerosis, and to the use of erythropoietin for this purpose and for the manufacture of a medicament for the intermittent treatment and/or intermittent prophylaxis of multiple scl... | 05/12/2011 |
| 20110105735 | METHODS OF PRODUCING AND PURIFYING PROTEINS Methods of producing and purifying proteins that comprise a glycan tag are provided. In some embodiments, a protein may be modified to include a glycan tag so as to facilitate production of the protein, e.g., by promoting protein secretion and/or promoting protein solub... | 05/05/2011 |
| 20110105734 | METHOD FOR PRODUCTION OF HUMAN ERYTHROPOIETIN Disclosed is a method for production of human erythropoietin. By the method, the cells are cultured in a serum-free medium with repetitive medium exchanges, in which medium exchange is carried out either by collecting 80 to 95% of the culture when viable cell density ha... | 05/05/2011 |
| 20110098452 | PURIFICATION OF MODIFIED CYTOKINES The invention provides an efficient method of purification of a modified cytokine. The process includes the use of a chromatographic technique for the purification of the desired cytokine. The purified cytokine can be used as a therapeutic composition.... | 04/28/2011 |
| 20110098451 | PEPTIDE-POLYMER CONJUGATES This invention relates to a conjugate of a polymer moiety and an erythropoietin moiety.... | 04/28/2011 |
| 20110092420 | SELENIUM CONTAINING MODIFYING AGENTS AND CONJUGATES The invention relates to a modifying agent comprising a water soluble polymer, wherein the water soluble polymer comprises at least one reactive selenium group, said reactive selenium group being capable of reacting with a thiol group thereby forming an —Se—S— bon... | 04/21/2011 |
| 20110065903 | Chromatographic methods The current invention comprises a method for the regeneration of a cation exchange chromatography column.... | 03/17/2011 |
| 20110059501 | Protein Glycosylation The present invention relates to methods for glycosylating a protein in which the protein is modified to include an alkyne and/or an azide group. The invention further relates to a protein glycosylated by these methods.... | 03/10/2011 |
